Trial Profile
A Randomized, Open-label, Five-period, Balanced Crossover Study to Evaluate the Relative Bioavailability of an Eltrombopag Powder for Oral Suspension (PfOS) Formulation Relative to the Commercial 25 mg Tablet Formulation and to Evaluate Administration of the PfOS Formulation With and Separated 2 Hours From a High Calcium Meal in Healthy Adult Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 Aug 2023
Price :
$35
*
At a glance
- Drugs Eltrombopag (Primary) ; Eltrombopag
- Indications Idiopathic thrombocytopenic purpura
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 15 Oct 2014 New trial record